The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.